1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202503299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Bahadır Bülbül und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp Campus, Düzce, Türkiye. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, ErbB Receptors, Acetamides. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A series of novel 1,2,4‐triazole‐acetamide derivatives was synthesized and evaluated for anticancer and hEGFR inhibitory activity. The compounds were obtained via multistep synthesis and characterized by spectroscopic methods. Cytotoxicity was tested against PC‐3, MCF‐7, A549, and K562 cell lines. Compounds 18 , 19 , and especially 24 showed notable antiproliferative effects, with compound 24 exhibiting higher selectivity and potency than gefitinib. It also induced apoptosis and inhibited migration in A549 and PC‐3 cells, while selectively promoting invasion in PC‐3, suggesting EMT‐related behavior. In vitro kinase assays revealed compound 20 as the most potent hEGFR inhibitor (IC 50 = 43.8 ± 1.3 nM). Molecular docking and 200 ns molecular dynamics simulations confirmed its stable interaction with EGFR, particularly involving Cys797. These findings highlight compounds 20 and 24 as promising candidates for further development as EGFR‐targeted anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp Campus, Düzce, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
- Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
- Department of Chemistry, Faculty of Science, Karadeniz Technical University, Trabzon, Türkiye.
- School of Medical & Allied Sciences, K. R. Mangalam University, Gurugram, India.
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.
Zitieren
APA
Bülbül, B., Kulabaş, N., Gürboğa, M., Ozakpınar, O. B., Çakmak, Ü., Tuncay, F. Ö., Kolcuoğlu, Y., Agrawal, M., Khan, M., & Küçükgüzel, İ. (2026). 1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202503299
Vancouver
Bülbül B, Kulabaş N, Gürboğa M, Ozakpınar OB, Çakmak Ü, Tuncay FÖ, et al. 1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202503299
BibTeX
@article{Blbl2026,
author = {Bülbül, Bahadır and Kulabaş, Necla and Gürboğa, Merve and Ozakpınar, Ozlem Bingöl and Çakmak, Ümmühan and Tuncay, Fulya Öz and Kolcuoğlu, Yakup and Agrawal, Mohit and Khan, Mujeeb and Küçükgüzel, İlkay},
title = {1,2,4‐Triazole‐Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202503299}
}
EUVIMED